The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

NCI formulary, moonshot and public-private partnerships

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Announcing the NCI Formulary, the Jan. 13 issue of The Cancer Letter includes comments suggesting the road to new therapies will now get “easier” and other comments indicated that industry and/or NCI collaborators will “not provide support other than drug access”.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Howard Fingert
Senior medical director in oncology clinical research, Takeda Pharmaceuticals Inc.
Table of Contents

YOU MAY BE INTERESTED IN

Byline
Howard Fingert
Senior medical director in oncology clinical research, Takeda Pharmaceuticals Inc.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account